Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

IPA reports record revenue and seeks funding for future growth

IPA's Q2 '23 earnings call highlighted record revenue, strategic program consolidation, and advancements in R&D. While facing cash needs and the need to raise funds, the company remains optimistic about future partnerships and the potential for data management transactions.

Immunoprecise Antibodies reports strong revenue growth and strategic collaborations

Immunoprecise Antibodies Ltd (IPA) had a strong quarter with revenue growth and valuable research collaborations, positioning the company for future success despite operational challenges.
IPA's focus on innovation, disruptive AI-driven collaborations, and strategic changes to boost profits highlight a positive growth trajectory and commitment to addressing unmet medical needs.

Immunoprecise Antibodies reports record revenue, eyes strategic partnerships for growth

IPA's Q4 '23 earnings call reflects strong revenue growth, strategic collaborations, and a focus on operational efficiency, positioning the company for future success.
While facing financial challenges and the need for fundraising, IPA's technological strengths, partnerships, and market opportunities offer avenues for growth and innovation.
The company's performance highlights resilience in the biotech sector, with a clear roadmap for enhancing shareholder value and advancing R&D capabilities.

Immunoprecise Antibodies Ltd posts strong Q1 earnings, eyes U.S. investors

Immunoprecise Antibodies Ltd (IPA) reports robust Q1 2024 earnings, marked by significant revenue growth and improved financial metrics. The company showcases strengths in strategic leadership, cost management, and expansion initiatives, while facing challenges in managing net losses and financial transparency. IPA has opportunities to capitalize on its strengths and attract more investors through the SEC shelf offering.

Immunoprecise Antibodies Ltd reports record Q2 revenue growth

IPA's Q2 2024 earnings call showcased robust revenue growth, operational improvements, and strategic initiatives driving the company forward.
While facing industry challenges, IPA's focus on client trust, cost management, and innovation positions it well for future success.
The company's commitment to governance, shareholder engagement, and exploring new revenue streams highlights a proactive approach to growth.

Immunoprecise Antibodies Ltd (IPA) reports strong Q3 performance and strategic investments

Immunoprecise Antibodies Ltd (IPA) delivered a robust performance in Q3 2024, marked by revenue growth, profit margin improvements, and strategic investments in BioStrand. While facing a net loss, IPA maintains a healthy cash balance and focuses on R&D efficiency. The company's strengths in innovation and customer commitment position it well for future growth, with opportunities to leverage its momentum for market expansion.

Immunoprecise Antibodies (IPA) reports 19% revenue growth in 2024

Immunoprecise Antibodies Ltd (IPA) delivered strong financial performance in fiscal year 2024, with revenue growth, reduced operating expenses, and successful product launches. Strategic collaborations and industry recognition highlight IPA's competitive strengths. Addressing commercialization challenges and seizing growth opportunities will be key focus areas for future success.

Immunoprecise Antibodies reports revenue growth and strategic advancements in Q1

IPA's Q1 2025 performance reflects revenue growth driven by VHH antibody programs and strategic inventory management.
The company's strengths lie in its AI-driven platform, strong pipeline, and balanced revenue generation models.
Challenges include maintaining financial consistency, effective inventory management, and staying competitive in the evolving market.
Opportunities for IPA include sustained growth through fee-for-service work, revenue diversification via licensing, and leadership in biotechnology innovation.

Immunoprecise Antibodies reports revenue growth amidst financial challenges in Q2 2025

Immunoprecise Antibodies Ltd's Q2 2025 performance reflects revenue growth but also increased expenses and a net loss, highlighting financial challenges.
Strategic strengths include industry profile enhancement, strong research collaborations, and a commitment to innovation.
Challenges lie in cost management, operational realignment post-divestiture, and the need for revenue growth.
Opportunities exist in collaborations with semiconductor companies, market expansion through BioStrand, and strategic financial restructuring.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

ImmunoPrecise Antibodies (NASDAQ: IPA ) stock is falling hard on Wednesday after the biotherapeutic company priced its shares in a public offering. This has ImmunoPrecise Antibodies offering 1.1 million shares of IPA stock for $1 per share.

Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) today announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share. All common shares in the underwritten public offering are to be sold by the Company. The Company expects the aggregate gross proceeds from this offering, to be approximately $1.1 million, before deducting the underwriting di.

IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced that it intends to offer and sell common shares in an underwritten public offering. All of the common shares in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering solely t.

IPA Announces Proposed Public Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director changes and upcoming financial reporting activities. New Board Chairman Mitch Levine joined the Board of Directors of IPA at IPA's recent Annual General Meeting and has been appointed as Chairman of the Board, bringing a wealth of experience from the l.

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

VICTORIA, BC / ACCESSWIRE / November 22, 2023 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has announced that its subsidiary, BioStrand®, has launched an advanced Retrieval Augmented Generation (RAG)-based Large Language Model (LLM) platform.

ImmunoPrecise's BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, BioStrand®, has published a preprint of its groundbreaking white paper titled, "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and Database Research" on bioRχiv. The publication delves into the intricacies of one of Bi.

BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, announces that its subsidiary, BioStrand®, has commercially launched its state-of-the-art Retrieval Augmented Generation (RAG)-based Large Language Model (LLM) platform. This pioneering platform seamlessly integrates with the Company's patented HYFT technology and LENSai platform, signifying a noteworth.

IPA's Subsidiary, BioStrand, Provides an Update on LENSai™

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments. IPA remains committed to expanding its contract research organization (CRO) capabilities and leveraging technology to drive innovation and efficiency. The pioneering work at IPA's subsidiary, BioStrand, reinforc.

IPA Provides Update on Growth Strategy and Recent Share Price Movement

VICTORIA, BC / ACCESSWIRE / October 20, 2023 / Biotechnology research involves a vast amount of complex information that spans different dimensions, such as the functions of proteins, the 3D structures of molecules and the genetic information encoded in DNA. Understanding these various dimensions is essential for comprehending biological systems and making meaningful predictions and insights.

Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data

VICTORIA, BC / ACCESSWIRE / October 13, 2023 / The introduction of artificial intelligence (AI) in healthcare has revolutionized the field, allowing for a more personalized approach to patient care. AI algorithms have the ability to process and analyze vast amounts of medical data, such as genetic information and DNA markers.

How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research

ImmunoPrecise Antibodies Ltd. (IPA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.

ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has named Kristin Taylor, MBA, CPA, as interim Chief Financial Officer. “On behalf of IPA, I thank Brad for his leadership and contributions and wish him every success in his future endeavors,” said Dr. James Kuo, Chairman of the Board. “I also welcome Kristin as interi.

ImmunoPrecise Antibodies Announces CFO Transition

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q1 2024 Earnings Conference Call September 14, 2023 10:30 AM ET Company Participants Jennifer Bath - President and Chief Executive Officer Barry Duplantis - Vice President of Client Relations Ilse Roodink - Chief Scientific Officer Brad McConn - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.

ImmunoPrecise Antibodies Ltd. (IPA) Q1 2024 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17.

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Tops Revenue Estimates

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023. “We are immensely proud to share that ImmunoPrecise Antibodies has commenced fiscal year 2024 with unparalleled vigor and determination. This quarter, we've not only achieved a record 21.3% surge in our revenue compared.

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday, September 14, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will ho.

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company. APPOINTMENT OF NEW DIRECTORS TO THE BOARD OF DIRECTORS In surveying the new appointees,.

IPA Announces Board Refreshment

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the following statement in response to the Schedule 13D filing made on July 7, 2023 by Ingalls & Snyder, LLC a New York-based investment manager. "IPA's Board of Directors and management team value constructive input and welcome open communication with our shareholders including Ingalls & Snyder,.

IPA Responds to 13D Filing

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other interested parties to participate in an upcoming interview hosted by Market Radius Research. Martin Gagel, founder of Market Radius Research, will join forces with Dr. Jennifer Bath, CEO of IPA, to delve into the intricate details of IPA's revolutionary platform. IPA's p.

ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q4 2023 Earnings Conference Call July 7, 2023 10:30 AM ET Company Participants Jennifer Bath - CEO Barry Duplantis - VP-Client Relations Ilse Roodink - Chief Scientific Officer Brad McConn - CFO Conference Call Participants Will McHale - Ingalls & Snyder Ramakanth Swayampakula - H.C.

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2023 Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive strides we made in the previous year. In the fiscal year ended April 30, 2023, we achieved a revenue of $20.7 million, marking a notable 6.7%.

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and fiscal year end 2023, on Friday, July 7, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will.

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma (IID) solution developed by its subsidiary, BioStrand®. Link to use case here The IID has long been a significant challenge in the biotechnology industry, with researchers and investors grappling with the complexities of integrating diverse dat.

IPA's Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and its subsidiary, BioStrand®. This innovative solution aims to significantly expedite the early stages of drug discovery by enabling the early elimination of less promising therapeutic candidates, thereby reducing time, cost, and the risk of failure du.

IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural.

News for Immunoprecise Antibodies Ltd Stock (IPA)